Phase II Clinical Trial of Mifepristone an Eye Drop Treatment for Steroid Associated Elevated Intraocular Pressure
Global bio-nanotech company pSivida Limited (NASDAQ:PSDV) (ASX:PSD) (Xetra:PSI) today announced the initiation of a Phase II clinical trial of Mifepristone (otherwise known as RU486) as an eye drop treatment for steroid associated elevated intraocular pressure (IOP).
The investigator-sponsored trial will involve up to 45 patients in the United States. pSivida will be supplying clinical trial material for this study and has filed a patent application on this product class.
Elevated IOP may occur in patients receiving steroidal treatment for chronic eye diseases. The trial will investigate the use of Mifepristone as a means to prevent elevation of IOP from intraocular steroid exposure. Mifepristone is a steroid receptor antagonist ("steroid blocker") already approved by the FDA. This study represents a potential new use of an existing drug, made possible by a new delivery system.
Filed under Eye Treatment |
You may also like to read
- Lumigan, Allergan's Intraocular Pressure Drug, Received FDA Approval
- Alcon Gets FDA Approval for Travatan-Z Which Reduce Elevated Intraocular Pressure
- Combination Antibiotic-Steroid for Ocular Inflammation Filed for FDA Approval
- Phase-II Clinical Trial of Drug Evizon for Wet Age-Related Macular Degeneration
- Novagali eye Treatment for Vernal Keratoconjunctivitis (VKC) Successful in Phase III Trial
- Can-Fite Begins Phase II Trials for Treatment of Symptoms of Keratitis Sicca (Dry-Eye Syndrome)
- Conductive Keratoplasty (non-Laser Refractive Procedure) Debuts in Denver and Colorado Springs
- Antibiotic Doxycycline Successfully Treats Eye Lymphoma
- Trabectome Promises Better Treatment For Gloucoma Patients
- Lucentis - Wet Macular Degeneration Drug is Highly Successful in Clinical Trials
February 16th, 2008 at 6:57 am
very little market for this drug
February 16th, 2008 at 9:50 am
no much use for this drug